Nct02141282 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nct02141282. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nct02141282 Today - Breaking & Trending Today

Venetoclax Elicits Responses in B-Cell Receptor–Pretreated CLL Regardless of Mutation Status

Treatment with single-agent venetoclax led to prolonged disease response in patients with chronic lymphocytic leukemia who had relapsed or become refractory to prior B-cell receptor inhibitors including ibrutinib and idelalisib, according to findings from a phase 2 study. ....

United States , Ohio State University , Jennifera Woyach , Newave Pharmacyclics , Leukemia Research Program , International Workshop , Ohio State Comprehensive Cancer Center , Division Of Hematology , Lancet Oncology , Treatment With Single Agent Venetoclax , Prolonged Disease Response In Patients With Chronic Lymphocytic Leukemia , Relapsed Or Refractory To Priorb Cell Receptor Inhibitors , 2023 International Workshop On Cll ,